Howard brings over twenty years of Canadian and U.S. corporate pharmaceutical senior commercial management experience to Verity Pharmaceuticals. Howard has also gained experience as a CEO within the medical market research and scientific communications industries.

Acquired corporate pharmaceutical brand experiences include the launch of the novel anti-infective Cipro. Additionally, Howard launched the anti-hypertensive agent Cardizem CD in Canada, moved to the American commercial team (Sanofi) on the cardiovascular portfolio, with national responsibilities on Cardizem CD ($1.3 billion in sales) and led the launch of Teczem (Co-promoted with Merck) in the American hypertension market.

For the past 14 years, Howard has focused his entrepreneurial passion in developing healthcare businesses in the biotech and pharmaceutical industries. The successful entrepreneurial ventures included a scientific publishing business and a primary health science market research company. Howard has also been involved in providing healthcare consultation services to Canadian, American and Internationally based pharmaceutical companies.

Howard studied at the University of Ottawa in Kinesiology and Health Sciences and completed a corporate-sponsored MBA certificate program in finance at Princeton University, NJ, and an executive MBA diploma course in International Business at the University of Western Ontario, London, Ontario.

Scott joins Verity with a background in strategic pharmaceutical planning, financial analytics, consulting, business development and tax planning within a multinational pharmaceutical organization. He achieved extensive executive decision-making accomplishments at Allergan Canada as the Senior Finance Manager, supporting senior management. During this time, Scott was responsible for overseeing the primary and specialty care business unit. Soon after, he was promoted to lead commercial analytics and planning within operations. There, his responsibilities included designing and implementing sales force compensation packages, business intelligence software, analytics and forecasting, as well as assessing ROI, resource sizing and allocation.
A CPA, Scott began his career in public accounting before becoming a senior financial analyst at a multinational traded company.

As the Verity CFO, Scott works within the Executive to contribute to the financial planning and governance of the company’s growth plans.

Jay joined Verity in 2019 as Chief Operating Officer and General Counsel and brings with him more than 13 years’ experience working with numerous multinational clients providing guidance within business governance and legal initiatives. During his career, he has undertaken numerous clients, managing complex business and negotiation positions within the Canadian market. Jay is recognized for his deep ethical sense, respect of others and talent for developing long-term business relationships. Prior to joining Verity Pharmaceuticals, Jay was a partner in a highly specialized mid-size litigation law firm, where he led numerous business and legal initiatives..

Jay holds a Bachelor of Laws degree from the University of Windsor and a  Bachelor of Arts from Concordia University. When not in the office, Jay is involved in a number of philanthropic initiatives, is an avid reader and spends time with his wife and three daughters.

Dr. Neil Fleshner graduated with a medical degree from the University of Toronto in 1988. He completed specialty training in urologic surgery and oncology from 1993 to 1996, received a Master’s in Public Health in epidemiology from Columbia University in 1997, and completed his oncology training at Memorial Sloan-Kettering Cancer Center. Dr. Fleshner is certified in both urology and epidemiology.

Dr. Fleshner is the Martin Barkin Professor and Chairman of Urology at the University of Toronto, and has been a urology fellow of the Royal College of Physicians and Surgeons of Canada for 23 years. Dr. Fleshner is also a Professor of Surgery at the University of Toronto. In the past, he has served as the Head of the Division of Urology at the University Health Network, and the Head of Genitourinary Cancer Site group at the Princess Margaret Hospital. He also holds the prestigious Love Chair in prostate cancer prevention at Princess Margaret Hospital.

Aside from surgical practice, Dr. Fleshner is the lead or co-investigator on numerous studies researching urologic cancer prevention with an emphasis on prostate cancer. His current projects include two randomized trials of intervention in prostate cancer, as well as laboratory work assessing prostate cancer metabolism. Dr. Fleshner has had a prolific research career, authoring over 400 scientific papers, books and book chapters on prostate disease. Dr. Fleshner is a highly sought after speaker, having delivered many talks and poster presentations all over the world over the last 23 years.

Tyler brings over 20 years of healthcare experience in marketing, sales, sales leadership and corporate/government affairs including 10+ years’ designing innovative multi-platform commercial and patient support solutions. Tyler’s experience and current role includes managing contract negotiations, design and deployment of complex contract and partnership agreements with organizations ranging from start-up biopharma to large Top 10 pharmaceutical companies.

Taniya has 20 years of experience in Canadian and Global pharmaceutical regulatory affairs. Taniya obtained her Hons. BSc in Molecular Genetics and Molecular Biology from the University of Toronto, followed by a PhD in Neuropharmacology from the University of Nottingham and an MBA from Boston College. Taniya then began pursuing her career in regulatory affairs. Her corporate background includes companies such as AstraZeneca, Boehringer Ingelheim, Apotex and Reckitt Benckiser.

She has led numerous successful filings, including NHPs, OTCs, Cosmetics, Disinfectants, Devices and Rx Drugs. The marketing authorizations obtained have been in a number of therapeutic areas including gastrointestinal, cardiovascular, respiratory and oncology and have included biologics and generics. Taniya joins the Verity team as Director of Regulatory Affairs.

Wayne brings over 25 years of broad-based healthcare experience spanning sales, marketing, data analytics, and commercial effectiveness to Verity Pharmaceuticals.

Wayne began his pharmaceutical career with Bayer Canada, then Pfizer in sales and product management roles prior to joining Bristol Myers-Squibb where he held a variety of marketing and corporate development positions in Canada and the U.S. For the past decade Wayne has held senior roles in business development and strategic consulting, advising to a host of start-up through large multinational pharmaceutical organizations.

Wayne holds a BEd – Science degree from the University of New Brunswick Canada and undertook graduate studies in science at York University, Toronto Canada.